ADAPTIMMUNE THERAPEUTICS PLC's ticker is ADAP and the CUSIP is 00653A107. A total of 81 filers reported holding ADAPTIMMUNE THERAPEUTICS PLC in Q2 2020. The put-call ratio across all filers is 1.08 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $95,000 | -41.7% | 88,339 | -8.1% | 0.00% | -50.0% |
| Q2 2022 | $163,000 | -83.5% | 96,110 | -49.6% | 0.00% | -77.8% |
| Q3 2021 | $985,000 | +13.0% | 190,550 | -6.9% | 0.01% | +12.5% |
| Q2 2021 | $872,000 | -41.3% | 204,775 | -26.8% | 0.01% | -46.7% |
| Q1 2021 | $1,486,000 | -1.4% | 279,815 | +0.1% | 0.02% | -11.8% |
| Q4 2020 | $1,507,000 | -4.2% | 279,550 | +41.8% | 0.02% | -26.1% |
| Q3 2020 | $1,573,000 | -23.5% | 197,170 | -4.0% | 0.02% | -17.9% |
| Q2 2020 | $2,057,000 | +45.8% | 205,448 | +63.5% | 0.03% | +154.5% |
| Q1 2018 | $1,411,000 | +103.6% | 125,655 | +21.0% | 0.01% | +120.0% |
| Q4 2017 | $693,000 | -8.1% | 103,816 | +12.7% | 0.01% | 0.0% |
| Q3 2017 | $754,000 | +162.7% | 92,100 | +44.1% | 0.01% | +150.0% |
| Q2 2017 | $287,000 | -14.6% | 63,892 | +4.9% | 0.00% | 0.0% |
| Q1 2017 | $336,000 | +22.2% | 60,896 | -10.5% | 0.00% | 0.0% |
| Q4 2016 | $275,000 | – | 68,024 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| MPM ASSET MANAGEMENT LLC | 5,555,461 | $4,405,481 | 2.16% |
| MPM BioImpact LLC | 5,095,912 | $4,041,058 | 0.94% |
| NEA Management Company, LLC | 17,079,778 | $13,544,624 | 0.90% |
| Syncona Portfolio Ltd | 1,377,294 | $1,092,194 | 0.69% |
| PFM Health Sciences, LP | 10,423,135 | $8,265,546 | 0.50% |
| TANG CAPITAL MANAGEMENT LLC | 4,387,238 | $3,479,080 | 0.32% |
| Long Focus Capital Management, LLC | 12,086,915 | $9,584,924 | 0.32% |
| Matrix Capital Management Company, LP | 38,974,185 | $30,906,529 | 0.32% |
| Acuitas Investments, LLC | 479,789 | $380,473 | 0.20% |
| Key Client Fiduciary Advisors, LLC | 336,620 | $266,940 | 0.16% |